Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

被引：192

作者：

Tatem, Kathleen S. ^{[1
]}

Quinn, James L. ^{[1
]}

Phadke, Aditi ^{[1
]}

Yu, Qing ^{[1
]}

Gordish-Dressman, Heather ^{[1
,2
]}

Nagaraju, Kanneboyina ^{[1
,2
]}

机构：

[1] Childrens Natl Med Ctr, Ctr Genet Med Res, Washington, DC 20010 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Dept Integrat Syst Biol, Washington, DC 20052 USA

来源：

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2014年 / 91期

基金：

美国国家卫生研究院;

关键词：

Behavior; Issue; 91; open field activity; functional testing; behavioral testing; skeletal muscle; congenital muscular dystrophy; muscular dystrophy; ANXIETY; MODEL; MICE; SEX;

D O I：

10.3791/51785

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The open field activity monitoring system comprehensively assesses locomotor and behavioral activity levels of mice. It is a useful tool for assessing locomotive impairment in animal models of neuromuscular disease and efficacy of therapeutic drugs that may improve locomotion and/or muscle function. The open field activity measurement provides a different measure than muscle strength, which is commonly assessed by grip strength measurements. It can also show how drugs may affect other body systems as well when used with additional outcome measures. In addition, measures such as total distance traveled mirror the 6 min walk test, a clinical trial outcome measure. However, open field activity monitoring is also associated with significant challenges: Open field activity measurements vary according to animal strain, age, sex, and circadian rhythm. In addition, room temperature, humidity, lighting, noise, and even odor can affect assessment outcomes. Overall, this manuscript provides a well-tested and standardized open field activity SOP for preclinical trials in animal models of neuromuscular diseases. We provide a discussion of important considerations, typical results, data analysis, and detail the strengths and weaknesses of open field testing. In addition, we provide recommendations for optimal study design when using open field activity in a preclinical trial.

引用

页数：7

共 21 条

[1] Raise standards for preclinical cancer research [J].

Begley, C. Glenn ;

Ellis, Lee M. .

NATURE, 2012, 483 (7391) :531-533

[2] Measuring normal and pathological anxiety-like behaviour in mice: a review [J].

Belzung, C ;

Griebel, G .

BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) :141-149

[3] Aged rats: Sex differences and responses to chronic stress [J].

Bowman, Rachel E. ;

Maclusky, Neil J. ;

Diaz, Samantha E. ;

Zrull, Mark C. ;

Luine, Victoria N. .

BRAIN RESEARCH, 2006, 1126 :156-166

[4] Omigapil Ameliorates the Pathology of Muscle Dystrophy Caused by Laminin-α2 Deficiency [J].

Erb, Michael ;

Meinen, Sarina ;

Barzaghi, Patrizia ;

Sumanovski, Lazar T. ;

Courdier-Frueh, Isabelle ;

Rueegg, Markus A. ;

Meier, Thomas .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (03) :787-795

[5] Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy [J].

Grounds, Miranda D. ;

Radley, Hannah G. ;

Lynch, Gordon S. ;

Nagaraju, Kanneboyina ;

De Luca, Annarnaria .

NEUROBIOLOGY OF DISEASE, 2008, 31 (01) :1-19

[6] Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies [J].

Kobayashi, Yvonne M. ;

Rader, Erik P. ;

Crawford, Robert W. ;

Campbell, Kevin P. .

NEUROMUSCULAR DISORDERS, 2012, 22 (01) :34-42

[7] A call for transparent reporting to optimize the predictive value of preclinical research [J].

Landis, Story C. ;

Amara, Susan G. ;

Asadullah, Khusru ;

Austin, Chris P. ;

Blumenstein, Robi ;

Bradley, Eileen W. ;

Crystal, Ronald G. ;

Darnell, Robert B. ;

Ferrante, Robert J. ;

Fillit, Howard ;

Finkelstein, Robert ;

Fisher, Marc ;

Gendelman, Howard E. ;

Golub, Robert M. ;

Goudreau, John L. ;

Gross, Robert A. ;

Gubitz, Amelie K. ;

Hesterlee, Sharon E. ;

Howells, David W. ;

Huguenard, John ;

Kelner, Katrina ;

Koroshetz, Walter ;

Krainc, Dimitri ;

Lazic, Stanley E. ;

Levine, Michael S. ;

Macleod, Malcolm R. ;

McCall, John M. ;

Moxley, Richard T., III ;

Narasimhan, Kalyani ;

Noble, Linda J. ;

Perrin, Steve ;

Porter, John D. ;

Steward, Oswald ;

Unger, Ellis ;

Utz, Ursula ;

Silberberg, Shai D. .

NATURE, 2012, 490 (7419) :187-191

[8] Chronic Systemic Therapy With Low-dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx Mice [J].

Malerba, Alberto ;

Sharp, Paul S. ;

Graham, Ian R. ;

Arechavala-Gomeza, Virginia ;

Foster, Keith ;

Muntoni, Francesco ;

Wells, Dominic J. ;

Dickson, George .

MOLECULAR THERAPY, 2011, 19 (02) :345-354

[9] Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies [J].

Nagaraju, K ;

Raben, N ;

Loeffler, L ;

Parker, T ;

Rochon, PJ ;

Lee, E ;

Danning, C ;

Wada, R ;

Thompson, C ;

Bahtiyar, G ;

Craft, J ;

van Huijsduijnen, RH ;

Plotz, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9209-9214

[10]

Nagaraju K., 2010, BEHAV LOCOMOTOR MEAS

← 1 2 3 →